PubRank

J J Fung

Author PubWeight™ 542.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993 8.76
2 The many faces of multivisceral transplantation. Surg Gynecol Obstet 1991 6.89
3 Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990 5.01
4 Intestinal transplantation in composite visceral grafts or alone. Ann Surg 1992 4.96
5 Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 1994 4.32
6 Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990 4.18
7 Liver transplantation in the United States, 1999-2008. Am J Transplant 2010 3.92
8 Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation 1995 3.63
9 Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 1991 3.40
10 Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991 3.34
11 Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc 1990 3.29
12 Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron 1987 3.26
13 Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery 1990 3.18
14 The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991 3.14
15 Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000 2.91
16 Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol 1986 2.84
17 Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc 1993 2.81
18 Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation 1992 2.75
19 Management of intestinal transplantation in humans. Transplant Proc 1992 2.62
20 Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990 2.60
21 Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation 1990 2.59
22 Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc 1991 2.59
23 The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997 2.57
24 FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994 2.50
25 Pregnancy after liver transplantation under tacrolimus. Transplantation 1997 2.50
26 Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990 2.48
27 Prioritization and organ distribution for liver transplantation. JAMA 1994 2.38
28 The antibody crossmatch in liver transplantation. Surgery 1986 2.33
29 The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 1994 2.32
30 Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg 1998 2.31
31 Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc 1991 2.28
32 Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg 1995 2.25
33 Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant 2015 2.24
34 Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006 2.22
35 Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999 2.22
36 Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992 2.20
37 Three years clinical experience with intestinal transplantation. J Am Coll Surg 1994 2.20
38 Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999 2.19
39 Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997 2.16
40 Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996 2.12
41 One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991 2.10
42 A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995 2.09
43 The side effects of FK 506 in humans. Transplant Proc 1990 2.08
44 Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet 1995 2.04
45 Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998 1.99
46 Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991 1.95
47 FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet 1990 1.94
48 Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation 1993 1.94
49 Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000 1.88
50 Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med 1995 1.88
51 Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996 1.86
52 Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995 1.83
53 Orthotopic liver transplantation in the mouse. Transplantation 1991 1.82
54 Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol 1997 1.81
55 Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc 1990 1.80
56 Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol 1991 1.78
57 Use of FK 506 in pediatric patients. Transplant Proc 1991 1.77
58 Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 1993 1.72
59 Transplantation. JAMA 1990 1.71
60 Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999 1.70
61 Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol 1985 1.65
62 Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation 1988 1.61
63 Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995 1.59
64 Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 1995 1.59
65 The spectrum of portal vein thrombosis in liver transplantation. Ann Surg 1991 1.58
66 De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014 1.57
67 Weaning of immunosuppression in liver transplant recipients. Transplantation 1997 1.57
68 Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc 1990 1.56
69 Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000 1.56
70 Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg 1999 1.55
71 Piggyback orthotopic intestinal transplantation. Surg Gynecol Obstet 1993 1.55
72 Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation 2000 1.53
73 Split tolerance induced by orthotopic liver transplantation in mice. Transplantation 1994 1.52
74 A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992 1.50
75 Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 1994 1.49
76 FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 1991 1.49
77 An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant 2001 1.48
78 Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc 1997 1.48
79 Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation 1992 1.45
80 The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998 1.42
81 Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 1997 1.41
82 Venous-right atrial bypass for superior vena cava thrombosis during orthotopic liver transplantation. Transplantation 1997 1.39
83 Organ allocation in the United States: where does it stand? Point. J Am Coll Surg 2001 1.38
84 Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997 1.36
85 Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem 2000 1.36
86 Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc 1987 1.36
87 Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997 1.36
88 OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc 1987 1.35
89 Neurologic complications of FK 506. Transplant Proc 1991 1.34
90 Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000 1.33
91 Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994 1.33
92 Assay of FK 506 in plasma. Transplant Proc 1990 1.32
93 Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992 1.32
94 The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000 1.31
95 Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995 1.31
96 Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc 1990 1.30
97 Management of splenic artery aneurysms: the significance of portal and essential hypertension. J Am Coll Surg 1999 1.28
98 Current status of intestinal transplantation in children. J Pediatr Surg 1998 1.28
99 Liver transplantation with cavoportal hemitransposition in the presence of diffuse portal vein thrombosis. Transplantation 1998 1.28
100 Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998 1.28
101 Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006 1.26
102 Comparison of the small intestine after multivisceral transplantation with the small intestines transplanted with portal or caval drainage. Transplant Proc 1992 1.26
103 ORTHOCLONE OKT3 in Treatment of Allografts Rejected Under Cyclosporine-Steroid Therapy. Transplant Proc 1986 1.25
104 Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg 1999 1.24
105 Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc 1991 1.24
106 Development and experience with an integrated system for transplantation telepathology. Hum Pathol 2001 1.23
107 Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation 1991 1.22
108 Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet 1993 1.21
109 Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation 1994 1.21
110 Fine-needle aspiration biopsy in pancreatic transplantation. Transplant Proc 1995 1.21
111 Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 1990 1.21
112 Dynamics of allospecific T lymphocyte infiltration in vascularized human allografts. Immunol Res 1986 1.20
113 Liver-derived DEC205+B220+CD19- dendritic cells regulate T cell responses. J Immunol 2001 1.18
114 Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1993 1.18
115 Tacrolimus in pediatric renal transplantation. Transplantation 1996 1.18
116 Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997 1.17
117 A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998 1.16
118 Disease gravity and urgency of need as guidelines for liver allocation. Hepatology 1994 1.16
119 Liver allograft rejection: an overview of morphologic findings. Am J Surg Pathol 1990 1.16
120 Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis 1996 1.15
121 Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol 1995 1.15
122 A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999 1.14
123 Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc 1990 1.14
124 A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995 1.13
125 A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996 1.13
126 Clinical intestinal transplantation: focus on complications. Transplant Proc 1992 1.11
127 Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000 1.10
128 Improved surgical technique for the establishment of a murine model of aortic transplantation. Microsurgery 1998 1.10
129 Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation 1993 1.10
130 Tacrolimus in renal transplantation. Transplant Proc 1996 1.10
131 Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999 1.09
132 Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992 1.09
133 Nutritional management of intestinal transplant recipients. Transplant Proc 1993 1.09
134 The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991 1.08
135 Functional cooperation of xenoproteins after hamster-to-rat liver transplantation: With particular reference to hamster C3 and secretory component for rat IgA. Xenotransplantation 1995 1.08
136 Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995 1.08
137 Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: a 44 month follow-up. Transplant Proc 1997 1.07
138 Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation 1997 1.07
139 Liver transplantation under cyclosporine: a decade of experience. Transplant Proc 1991 1.07
140 In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation 1995 1.06
141 Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc 1991 1.06
142 Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol 1993 1.06
143 Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993 1.05
144 Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997 1.03
145 Excision and immediate revascularization for hepatic artery pseudoaneurysm following liver transplantation. Transplant Proc 1999 1.03
146 Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993 1.03
147 Predicting outcomes after liver transplantation. A connectionist approach. Ann Surg 1994 1.02
148 Internal hernia and volvulus of the small bowel following liver transplantation. Transpl Int 1997 1.02
149 Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc 1991 1.01
150 A new xenogeneic radiation chimera (hamster-to-rat). Transplantation 1994 1.01
151 Microbiologic surveillance as part of human islet transplantation: results of the first 26 patients. Transplant Proc 1992 1.01
152 Analysis of T lymphocytes infiltrating human hepatic allografts. Transplant Proc 1987 1.00
153 Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999 1.00
154 Split-liver transplantation: a comparison of ex vivo and in situ techniques. J Pediatr Surg 2000 1.00
155 Concomitant infusion of unmodified donor bone marrow into unconditioned recipients of intestinal allografts. Transplant Proc 1996 1.00
156 Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation 1998 1.00
157 Upper-abdominal exenteration in transplantation for extensive malignancies of the upper abdomen--an update. Transplantation 1991 1.00
158 Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc 1995 0.99
159 Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl Surg 1999 0.99
160 FK 506 dosage in human organ transplantation. Transplant Proc 1990 0.99
161 The liver transplant waiting list--a single-center analysis. Transplantation 1991 0.99
162 Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc 1997 0.98
163 Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Am J Transplant 2010 0.98
164 Prospects of clinical xenotransplantation. Transplant Proc 1994 0.98
165 Role of UW solution and sodium nitroprusside in reperfusion of liver xenografts from guinea-pig to rat. Xenotransplantation 1999 0.97
166 Composition of human islet cell preparations for transplantation. Acta Diabetol 1992 0.97
167 Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998 0.97
168 Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998 0.97
169 Gastrointestinal bleeding after liver transplantation. Transplantation 1997 0.96
170 Recognition of major histocompatibility complex antigens on cultured human biliary epithelial cells by alloreactive lymphocytes. Hepatology 1991 0.96
171 Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996 0.96
172 Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996 0.96
173 Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J Immunol 2001 0.96
174 Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999 0.96
175 The politics of grafting cadaver kidneys. Lancet 1996 0.95
176 Hepatic artery angioplasty after liver transplantation: experience in 21 allografts. J Vasc Interv Radiol 1995 0.95
177 Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000 0.95
178 Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001 0.95
179 Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation 1997 0.95
180 Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc 1991 0.95
181 The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. J Surg Oncol Suppl 1993 0.95
182 Allogeneic orthotopic liver transplantation in mice: a preliminary study of rejection across well-defined MHC barriers. Transplant Proc 1991 0.95
183 An attempt to reverse diabetes by delayed islet cell transplantation in humans. Transplant Proc 1997 0.94
184 Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997 0.94
185 One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc 1995 0.94
186 Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. Transplant Proc 1991 0.94
187 FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991 0.93
188 Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc 1990 0.93
189 Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 1991 0.93
190 Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001 0.93
191 Clinical intestinal transplantation. Transplant Proc 1993 0.92
192 Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc 1997 0.92
193 Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Transplant Proc 1999 0.92
194 Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004 0.92
195 Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997 0.92
196 Cardiac operations in solid-organ transplant recipients. Ann Thorac Surg 1997 0.92
197 Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation 1999 0.92
198 Explanation for loss of the HLA matching effect. Transplant Proc 1995 0.91
199 Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002 0.91
200 Human islet transplantation: results of the first 37 patients. Transplant Proc 1995 0.91
201 Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998 0.91
202 Isolation of the regulatory regions and genomic organization of the porcine alpha1,3-galactosyltransferase gene. Transplantation 2000 0.91
203 Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation 1994 0.91
204 Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004 0.91
205 Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc 1993 0.90
206 Intestinal transplantation in humans under FK 506. Transplant Proc 1993 0.90
207 Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000 0.90
208 Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc 1996 0.90
209 Isolation and primary cultures of human intrahepatic bile ductular epithelium. In Vitro Cell Dev Biol 1988 0.90
210 HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation 1997 0.89
211 A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 2000 0.89
212 FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 1991 0.89
213 Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001 0.89
214 Lymphocytes of bronchoalveolar lavages from heart-lung transplant recipients. J Heart Transplant 1987 0.89
215 Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transpl 2001 0.89
216 Pyruvate inhibits the chronic damage which ensues after ischemia/reperfusion injury of kidneys. Transplant Proc 1999 0.89
217 Human islet allotransplantation under FK 506. Transplant Proc 1991 0.89
218 Hamster coagulation and serum proteins in rat recipients of hamster xenografts. Transplantation 1993 0.88
219 Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. Transplant Proc 1990 0.88
220 Changes in renal function after liver transplantation under FK 506. Transplant Proc 1991 0.88
221 Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts. Immunology 1996 0.87
222 Late-onset renal failure after liver transplantation: role of posttransplant alcohol use. Transplantation 2000 0.87
223 Effect of OKT3 on survival and rate of retransplantation. Transplant Proc 1987 0.87
224 Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation 1997 0.87
225 Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc 1991 0.87
226 Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000 0.87
227 Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure. Dig Dis Sci 2000 0.86
228 Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998 0.86
229 Rapid en bloc technique for liver and pancreas procurement. Transplant Proc 1997 0.86
230 Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998 0.86
231 Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplant Proc 2002 0.86
232 HLA antigen expression on cultured human arterial endothelial cells. Tissue Antigens 1988 0.86
233 Liver transplantation in patients over sixty years of age. Transplantation 1991 0.86
234 Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant Proc 1998 0.86
235 Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005 0.86
236 Synergistic effect of cold and warm ischemia time on postoperative graft function and outcome in human liver transplantation. Transplant Proc 2004 0.86
237 Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation 2000 0.86
238 Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998 0.86
239 Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997 0.86
240 Urgent revascularization of liver allografts after early hepatic artery thrombosis. Transplantation 1996 0.86
241 Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc 1993 0.85
242 Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc 2001 0.85
243 Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994 0.85
244 Application of recipient-derived dendritic cells to induce donor-specific T-cell hyporesponsiveness. Transplant Proc 2004 0.85
245 Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation 2001 0.85
246 Outcome of liver transplantation using donors 60 to 79 years of age. Transplant Proc 1995 0.85
247 FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991 0.85
248 Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001 0.85
249 Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991 0.85
250 Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron 1987 0.85
251 Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol 1999 0.85
252 Transjugular intrahepatic portosystemic shunt in patients with end-stage liver disease: results in 85 patients. Liver Transpl Surg 1996 0.85
253 Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000 0.84
254 Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center. Transplant Proc 2002 0.84
255 The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transplant Proc 1991 0.84
256 Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transpl Surg 1997 0.84
257 Interaction between FK 506 and cyclosporine in dogs. Transplant Proc 1991 0.84
258 Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001 0.84
259 HLA histocompatibility and liver transplant survival. Transplant Proc 1987 0.84
260 Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation. Transplant Proc 1997 0.84
261 Spindle cell tumor of the portal vein. J Surg Oncol 1995 0.84
262 Liver-derived dendritic cells induce donor-specific hyporesponsiveness: use of sponge implant as a cell transplant model. Cell Transplant 2001 0.84
263 Role of splenectomy in human liver transplantation under modern-day immunosuppression. Dig Dis Sci 1998 0.84
264 Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. Transplantation 1995 0.84
265 Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995 0.83
266 Presensitization by skin grafting from major histocompatibility complex class I or major histocompatibility complex class II deficient mice identifies class I antigens as inducers of allosensitization. Immunology 1995 0.83
267 Interleukin-2 and interleukin-12 mediate distinct effector mechanisms of liver allograft rejection. Liver Transpl Surg 1997 0.83
268 Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc 1991 0.83
269 Bacterial translocation in clinical intestinal transplantation. Transplant Proc 2000 0.83
270 Interferon-gamma induced expression of MHC antigens facilitates identification of donor cells in chimeric transplant recipients. Cell Transplant 1994 0.83
271 Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Transplantation 1998 0.83
272 High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc 1997 0.83
273 Split liver transplantation using Hemiliver graft in the MELD era: a single center experience in the United States. Am J Transplant 2014 0.83
274 Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. Am J Hosp Pharm 1992 0.83
275 Relationship between the diagnosis, preoperative evaluation, and prognosis after orthotopic liver transplantation. Ann Surg 1988 0.83
276 Influence of donor cardiopulmonary arrest in human liver transplantation: possible role of ischemic preconditioning. Hepatology 2000 0.83
277 Concanavalin A simultaneously primes liver hematopoietic and epithelial progenitor cells for parallel expansion during liver regeneration after partial hepatectomy in mice. Hepatology 2000 0.83
278 Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000 0.83
279 Infectious complications after human small bowel transplantation. Transplant Proc 1992 0.82
280 Quality of life after intestinal transplantation and on total parenteral nutrition. Transplant Proc 1998 0.82
281 Use of DNA amplification for diagnosis of cytomegalovirus enteritis after intestinal transplantation. Gastroenterology 1997 0.82
282 The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc 2000 0.82
283 Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999 0.82
284 The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us? Transplant Proc 1995 0.82
285 Apoptosis of graft-infiltrating cytotoxic T cells: a mechanism underlying "split tolerance" in mouse liver transplantation. Transplant Proc 1997 0.82
286 Reducing the length of stay after kidney transplantation--the intensive outpatient unit. Clin Transplant 1998 0.82
287 An attempt to induce tolerance with infusion of donor bone marrow in organ allograft recipients. Adv Exp Med Biol 1997 0.82
288 Mouse liver transplantation tolerance: the role of hepatocytes and nonparenchymal cells. Transplant Proc 1995 0.82
289 Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 2001 0.82
290 Tc-99m hexamethylpropylene amine oxime scintigraphy in the diagnosis of brain death and its implications for the harvesting of organs used for transplantation. Clin Nucl Med 2000 0.82
291 Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up. Transplant Proc 2001 0.82
292 "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation 1996 0.82
293 Treatment of Cogan's syndrome with FK 506: a case report. Transplant Proc 1991 0.82
294 Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999 0.81
295 Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001 0.81
296 Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 1998 0.81
297 Histologic monitoring of human small bowel allografts with clinical correlation. Transplant Proc 1992 0.81
298 Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Transplantation 1998 0.81
299 Small bowel transplantation: current progress and clinical application. Hepatogastroenterology 1996 0.81
300 Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc 1991 0.81
301 Sequential infiltration of class I and class II specific alloreactive T cells in human cardiac allografts. Transplant Proc 1987 0.81
302 Association of HLA Compatibility and Decreased Liver Transplant Survival. Transplant Proc 1988 0.81
303 Human liver xenotransplantation. Xeno 1993 0.81
304 Islet cell allotransplantation in diabetic patients. Histologic findings in four adults simultaneously receiving kidney or liver transplants. Am J Pathol 1992 0.81
305 Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc 2001 0.81
306 Hepatic transplantation during pregnancy and the puerperium. J Matern Fetal Med 1997 0.81
307 Enteric-drained pancreas transplants monitored by fine-needle aspiration biopsy. Transplant Proc 1997 0.80
308 Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993 0.80
309 Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc 1995 0.80
310 FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991 0.80
311 Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: a case report and review of the literature. Transplantation 2000 0.80
312 Treatment of isolated pancreatic islets to reverse pancreatectomy-induced and insulin-dependent type I diabetes in humans: a 6-year experience. Transplant Proc 1997 0.80
313 An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1999 0.80
314 Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation 1999 0.80
315 Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med 1993 0.80
316 Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant 1999 0.80
317 Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg 2000 0.80
318 Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. Liver Transpl Surg 1999 0.80
319 Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998 0.80
320 Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998 0.80
321 Adenovirus-mediated gene transfer to liver grafts: an improved method to maximize infectivity. Transplantation 1998 0.79
322 Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 1997 0.79
323 The dichotomous functions of passenger leukocytes in solid-organ transplantation. Adv Nephrol Necker Hosp 1995 0.79
324 Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation 1999 0.79
325 Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001 0.79
326 Comparison of the regulatory regions of the alpha1,3galactosyltransferase gene between murine and porcine species. Transplant Proc 2001 0.79
327 "Pants" vein jump graft for portal vein and superior mesenteric vein thrombosis in transplantation of the liver. J Am Coll Surg 1996 0.79
328 Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. Transplant Proc 1997 0.79
329 Transplantation unresponsiveness induced by liver allografts in mouse strains with various histocompatibility disparities. Transplant Proc 1992 0.79
330 Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation 1997 0.79
331 Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998 0.79
332 Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation 2001 0.79
333 Transduction of dendritic cells with adenoviral vectors encoding CTLA4-Ig markedly reduces their allostimulatory activity. Transplant Proc 1999 0.79
334 Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc 1997 0.79
335 Liver and kidney transplantation from non-heart beating donors: the Pittsburgh experience. Transplant Proc 1995 0.79
336 Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 2001 0.79
337 Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 1997 0.79
338 Two-year experience with FK 506 in pediatric patients. Transplant Proc 1993 0.78
339 Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. Transplant Proc 1991 0.78
340 A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001 0.78
341 Serum protein immunogenicity: implications for liver xenografting. Electrophoresis 2000 0.78
342 Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc 1996 0.78
343 Early recipient-donor switch of the complement type after liver xenotransplantation. Immunol Invest 1998 0.78
344 Intestinal transplantation for patients with short gut syndrome and hypercoagulable states. Transplant Proc 2000 0.78
345 Propagation of cells expressing donor phenotype (MHC class I, II and Y-chromosome) from the bone marrow of murine liver allograft recipients in response to GM-CSF in vitro. Transplant Proc 1995 0.78
346 Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl 2000 0.78
347 Concordant hamster-to-rat liver xenotransplantation leads to hyperlipidemia. Transplant Proc 2000 0.78
348 Posttransplant lymphoproliferative disorders in small bowel allograft recipients. Transplant Proc 2000 0.78
349 Clonal and morphological variation in a posttransplant lymphoproliferative disorder: evolution from clonal T-cell to clonal B-cell predominance. Hum Pathol 1998 0.78
350 Primary cultures of human intrahepatic (biliary) epithelial cells. Transplant Proc 1988 0.78
351 Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology 2000 0.78
352 Living donor liver transplantation: ethics and safety. Transplant Proc 2003 0.78
353 Liver transplantation for acute liver failure: outcome analysis. J Viral Hepat 1997 0.78
354 Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999 0.78
355 Patterns of inflammatory vascular endothelial changes in murine liver grafts. Transplantation 1995 0.78
356 Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. Transplant Proc 1992 0.78
357 The two-way paradigm of transplantation immunology. Clin Immunol Immunopathol 1996 0.78
358 Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc 1993 0.78
359 Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc 2002 0.78
360 Experience with liver and kidney allografts from non-heart-beating donors. Transplant Proc 1995 0.78
361 Percutaneous ultrasound-guided pancreas allograft biopsy: a single-center experience. Transplant Proc 2005 0.78
362 Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc 1996 0.78
363 Second-set rejection of mouse liver allografts is dependent on radiation-sensitive nonparenchymal cells of graft bone marrow origin. Transplantation 1996 0.77
364 Clinical intestinal transplantation in 1998: Pittsburgh experience. Acta Gastroenterol Belg 1999 0.77
365 Pretreatment of recipients (nude rat) with donor antigens leads to prolonged survival of hamster heart xenografts. Transplant Proc 1996 0.77
366 Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts. Transplant Proc 1997 0.77
367 Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection. Transplantation 1999 0.77
368 The University of Pittsburgh: a three and three-quarter-year experience with cadaveric renal transplantation under the point system. Clin Transpl 1989 0.77
369 Natural history of Epstein-Barr viral load in peripheral blood of pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disorder. Transplant Proc 1999 0.77
370 Evidence for early Th 2 T cell predominance in xenoreactivity. Transplantation 1993 0.77
371 Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. Transplant Proc 1998 0.77
372 Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001 0.77
373 Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest 1996 0.77
374 Adenovirus-mediated gene therapy to liver grafts: successful gene transfer by donor pretreatment. Surgery 2000 0.77
375 Documentation in bone-marrow-augmented organ recipients of the presence of dendritic cell progenitors of donor origin. Transplant Proc 1997 0.77
376 Transfection with genes encoding CTLA4Ig mediated by adenoassociated virus vectors prolongs survival of heart allografts. Transplant Proc 2001 0.77
377 Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transplant Proc 1998 0.77
378 Recipient pretreatment with mammalian IL-10 prolongs mouse cardiac allograft survival by inhibition of anti-donor T cell responses. Transplant Proc 1999 0.77
379 Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. Transplant Proc 1991 0.77
380 Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplant Proc 2001 0.77
381 Immunosuppressive therapy. Surg Clin North Am 1999 0.77
382 Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences. Transplant Proc 1993 0.76
383 Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine. Transplant Proc 1993 0.76
384 Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc 1991 0.76
385 Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation 1998 0.76
386 Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997 0.76
387 Building clinical classifiers using incomplete observations--a neural network ensemble for hepatoma detection in patients with cirrhosis. Methods Inf Med 1995 0.76
388 Chimerism after organ transplantation. Curr Opin Nephrol Hypertens 1997 0.76
389 Human islet allotransplantation in 18 diabetic patients. Transplant Proc 1992 0.76
390 Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl Surg 1997 0.76
391 The effect of splenectomy on cardiac and liver xenografts in the nude rat. Transplant Proc 1994 0.76
392 Hepatocytes and liver nonparenchymal cells induce apoptosis in activated T cells. Transplant Proc 1999 0.76
393 Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999 0.76
394 Alcoholic liver disease and transplantation. Transplant Proc 2003 0.76
395 Valuation of transmission of porcine endogenous retrovirus into patients subjected to hemoperfusion using an extracorporeal bioartificial liver support system. Transplant Proc 2001 0.76
396 Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc 1999 0.76
397 Influence of donor condition on postoperative graft survival and function in human liver transplantation. Transplant Proc 2000 0.76
398 Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc 1997 0.76
399 Cytidine potentiates the inhibitory effect of brequinar sodium on xeno-MLR, antibody production, and concordant hamster to rat cardiac xenograft survival. Ann N Y Acad Sci 1993 0.76
400 Performance of multi-layer feedforward neural networks to predict liver transplantation outcome. Methods Inf Med 1996 0.76
401 Acute pancreatitis after liver transplantation: incidence and contributing factors. Transpl Int 1995 0.76
402 Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention. Graft (Georget Tex) 1998 0.76
403 Enhancement of dendritic cell tolerogenicity by genetic modification using adenoviral vectors encoding cDNA for TGF beta 1. Transplant Proc 1999 0.76
404 Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc 2001 0.76
405 Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc 2002 0.76
406 Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. Transplant Proc 1994 0.76
407 Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival. Transplant Proc 1999 0.76
408 Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. Bone Marrow Transplant 1993 0.76
409 Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc 1993 0.76
410 Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Transplantation 1999 0.76
411 The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc 1991 0.75
412 Perioperative treatment with phosphatidic acid inhibitor (Lisofylline leads to prolonged survival of hearts in the guinea pig to rat xenotransplant model. Transplant Proc 1996 0.75
413 Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity 1994 0.75
414 Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. Transplant Proc 1996 0.75
415 Endothelin-1 receptor blockade and its effect on chronic rejection. Transplant Proc 1999 0.75
416 Metabolic changes in the recipient after successful liver xenotransplantation in the rat. Transplant Proc 1994 0.75
417 Long-term survival of heart and liver xenografts with splenectomy and FK 506. Transplant Proc 1993 0.75
418 Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. Transplant Proc 1997 0.75
419 Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc 1997 0.75
420 Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc 1999 0.75
421 Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. Transplant Proc 2000 0.75
422 Translocation of bacteria from the gastrointestinal tract: protection afforded by lisofylline. Transplant Proc 1999 0.75
423 A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc 2002 0.75
424 Liver transplantation for alcoholic liver disease, viral hepatitis, and hepatic neoplasms. Transplant Proc 1991 0.75
425 The bidirectional paradigm of transplant immunology. Ann N Y Acad Sci 1995 0.75
426 Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant Proc 1991 0.75
427 Alopecia as a consequence of tacrolimus therapy. Transplantation 1998 0.75
428 Posttransplant hypertension in blacks versus nonblacks. Transplant Proc 1993 0.75
429 Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 2001 0.75
430 Outcome of human islet isolation and allotransplantation in 20 consecutive cases. Diabetes Nutr Metab 1992 0.75
431 Detection of intrahepatic human islets following combined liver-islet allotransplantation. Pancreas 1992 0.75
432 Between Scylla and Charybdis. Ann Surg 1995 0.75
433 Donor bone marrow infusion in liver recipients: effect on the occurrence of acute cellular rejection. Transplant Proc 2001 0.75
434 Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc 1993 0.75
435 Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation 1996 0.75
436 The role of antibodies in liver graft-induced tolerance in mice: passive transfer of serum and effect of recipient B-cell depletion. Transplant Proc 1995 0.75
437 Resource use in liver transplantation. JAMA 1999 0.75
438 Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant 1997 0.75
439 Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis 1998 0.75
440 Chimerism and xenotransplantation. New concepts. Surg Clin North Am 1999 0.75
441 Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc 1995 0.75
442 The long-term efficacy of multivisceral transplantation. Transplant Proc 2000 0.75
443 Evidence for engraftment of human bone marrow cells in non-lethally irradiated baboons. Transplantation 1997 0.75
444 Nutritional management of intestinal allograft recipients. Transplant Proc 1998 0.75
445 Perioperative donor bone marrow infusion in recipients of organ allografts. Transplant Proc 1997 0.75
446 Cytokine profile in graft-versus-host disease after small bowel transplantation. Transplant Proc 1996 0.75
447 Mechanisms underlying the development of T-cell tolerance following interruption of signalling at the CD28/B7 and CD40/gp39 interface. Transplant Proc 1999 0.75
448 Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc 1999 0.75
449 Posttransplant diabetes in pediatric recipients on tacrolimus. Transplantation 1999 0.75
450 Daily serum inflammatory cytokine (tumor necrosis factor-alpha, interleukin-6) monitoring in liver transplantation focusing on allograft rejection: a five-case report. Transplant Proc 1996 0.75
451 Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. Transplant Proc 1996 0.75
452 CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplant Proc 1991 0.75
453 Donor-specific transfusion in the nude rat prolongs survival of subsequently transplanted hamster cardiac xenografts. Transplant Proc 1997 0.75
454 Pathologic analysis of recurrent posttransplant lymphoproliferative disorders. Transplant Proc 1995 0.75
455 Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc 2001 0.75
456 Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc 1991 0.75
457 Use of MHC class I or II "knock out" mice to delineate the role of these molecules in acceptance/rejection of xenografts. Transplant Proc 1996 0.75
458 The antigenicity of serum proteins and their role in xenograft rejection. Transplant Proc 1996 0.75
459 Effect of recipient race on waiting time for renal transplantation at the University of Pittsburgh. Transplant Proc 1993 0.75
460 Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995 0.75
461 Outcome of kidney transplantation in African-Americans using tacrolimus. Transplant Proc 1997 0.75
462 Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. Transplant Proc 1992 0.75
463 Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc 1998 0.75
464 Allospecificity of liver allograft-derived lymphocytes and correlation with clinicopathologic findings. Transplant Proc 1988 0.75
465 Cytidine potentiates the inhibitory effect of brequinar sodium on concordant cardiac xenograft rejection. Transplant Proc 1994 0.75
466 Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 1996 0.75
467 Managing hepatic bleeding with autologous plasma/collagen-based fibrin sealant. Arch Surg 2001 0.75
468 Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Clin Pharmacol Ther 1998 0.75
469 Cross-tolerance of recipient-derived transforming growth factor-beta dendritic cells. Transplant Proc 2007 0.75
470 A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998 0.75
471 Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in rats. Cell Transplant 1994 0.75
472 The pharmacodynamics of pentobarbital following FK 506 therapy. Transplant Proc 1991 0.75
473 Cytokine messenger RNA profiles in hamster-to-rat liver xenografts. Transplant Proc 1993 0.75
474 Loss of serum bicarbonate after discordant liver xenotransplantation. Transplant Proc 2000 0.75
475 Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Transplant Proc 1994 0.75
476 The immunolymphatic theory of chronic rejection. Transplant Proc 1997 0.75
477 Ischemia/reperfusion injury induces chronic changes in the small bowel. Transplant Proc 2000 0.75
478 Survival of human hepatocellular aggregates in athymic mice. Transplant Proc 1992 0.75
479 The role of Fas/FasL apoptotic pathway in the development of chronic rejection. Transplant Proc 1999 0.75
480 Intrahepatic human islet transplantation at the University of Pittsburgh: results in 25 consecutive cases. Transplant Proc 1992 0.75
481 Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc 1997 0.75
482 Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 days. Transplantation 2001 0.75
483 Preservation injury and acute rejection of rat intestinal grafts: protection afforded by pyruvate. J Gastrointest Surg 2000 0.75
484 Orthotopic liver transplantation in U.S. veterans under primary tacrolimus immunosupression. Surg Technol Int 1996 0.75
485 Should reimbursement be denied for liver transplantation in patients with hepatocellular carcinoma? JAMA 1997 0.75
486 Human islet allograft follow-up: long-term islet function and over 3 years of insulin independence. Transplant Proc 1994 0.75
487 Xenoreactivity in mouse + rat-->mouse chimeras. Transplant Proc 1993 0.75
488 FcgammaRllc 13Q/STP polymorphism influences the antibody-dependent cytotoxicity levels triggered by natural killer cells against pig aortic endothelial cells. Transplant Proc 2001 0.75
489 Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses. Transplant Proc 2001 0.75
490 Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Transplant Proc 1999 0.75
491 Reconstruction of an abnormal hepatic vein in a donor liver: a case report. Transplantation 1998 0.75
492 FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc 1994 0.75
493 Suppression of alloreactive T-cell activation by murine liver F4/80+ accessory cells and kinetics of intrahepatic F4/80+ cells following liver transplantation. Transplant Proc 1995 0.75
494 Hepatitis C virus and renal failure. Transplant Proc 2003 0.75
495 A simplified method for growing dendritic cells from rat bone marrow. Adv Exp Med Biol 1995 0.75
496 Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord 1999 0.75
497 Maturation of B-cell clones. Prog Clin Biol Res 1980 0.75
498 Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. Transplant Proc 2000 0.75
499 Early clinical and histologic viability of human liver-small intestinal allografts after implantation. Clin Transplant 1994 0.75
500 Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg 1999 0.75
501 FK 506 interaction with danazol. Lancet 1993 0.75
502 Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc 1995 0.75
503 Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease. Transplant Proc 2000 0.75
504 Role of MHC class I and CD8(+) T cells in the pathogenesis of chronic rejection. Transplant Proc 2001 0.75
505 Immunological factors influencing liver graft survival. Gastroenterol Clin North Am 1988 0.75
506 Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity. Transplant Proc 2001 0.75
507 A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc 1999 0.75
508 Hamster-to-rat bone marrow xenotransplantation and humoral graft vs. host disease. Xenotransplantation 2001 0.75
509 [Experience of orthotopic liver transplantation from non-heart-beating donors at the University of Pittsburgh Medical Center]. Nihon Geka Gakkai Zasshi 1999 0.75
510 Blockade of the CD28/B7 and CD40/CD40L costimulatory pathways does not ameliorate chronic rejection in a mouse aortic allograft model of direct antigen presentation. Transplant Proc 2001 0.75
511 Quantitative assessment of the development of hepatoma in a buffalo rat model. Transplant Proc 1997 0.75
512 Cadaveric liver donors; what are the limits? Transplant Proc 1996 0.75
513 The patient with chronic hepatitis C. Liver Transpl Surg 1996 0.75
514 Advances in hepatitis B virus infection. Transplant Proc 2003 0.75
515 I-131 orthoiodohippurate assessment of renal function after heart transplantation. Clin Nucl Med 1999 0.75
516 Long-term nutritional monitoring after clinical intestinal transplantation. Transplant Proc 1998 0.75
517 Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc 2000 0.75
518 The protection from humoral rejection given by a liver xenograft is species-specific and non-MHC restricted. Transplant Proc 1995 0.75
519 Immune complex disease in immunosuppressed rat recipients of hamster liver xenografts. Transplant Proc 2001 0.75
520 Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA. Transplant Proc 2001 0.75
521 The effect of thymus transplantation on allograft rejection in thymectomized bone marrow chimeras. Transplant Proc 1990 0.75
522 The role of liver stromal cells in dendritic cells development in mice. Transplant Proc 2010 0.75
523 The latest advances in liver transplantation at the pittsburgh transplantation institute: evolution of FK506, liver-intestinal transplantation, clinical xenotransplantation, and the induction of graft acceptance. Surg Technol Int 1994 0.75
524 Short exposure to hepatocyte growth factor stimulates adult human pancreatic beta-cell proliferation. Transplant Proc 1995 0.75
525 Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. Transplant Proc 1994 0.75
526 Presentation of MHC-disparate donor antigens predominantly by the indirect pathway results in the development of posttransplant vasculopathy: salutary effects of perioperative costimulatory blockade. Transplant Proc 2001 0.75
527 Bronchoalveolar macrophage-lymphocyte reactivity in heart-lung transplant recipients. Transplant Proc 1987 0.75
528 [Clinical experience with FK 506]. Presse Med 1991 0.75
529 Functional studies of in vivo committed lymphocytes propagated from organ transplants. Prog Clin Biol Res 1986 0.75
530 Modified temporary end-to-side portocaval shunt in liver and small bowel transplantation. Pediatr Transplant 2001 0.75
531 Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl 1999 0.75
532 Combined veno-venous bypass and high volume hemofiltration during orthotopic liver transplantation. ASAIO J 1994 0.75
533 The combined use of sublethal irradiation and costimulatory blockade to generate mixed bone marrow chimeras. Transplant Proc 1999 0.75